Novosibirsk Plant of Medical preparations, Canada
Title: Teratogens against cancer
Vladimir Pak, Ph.D. in Molecular Biology from the Institute of Bioorganic Chemistry, Moscow with over 30 years of post doctoral experience in Virology, Biotechnology and Oncology. The author of 7 patents related to API research and medicines manufacturing that excelled in quality to similar drugs on the Russian pharmaceutical market or replaced foreign drugs. Invented anti-cancer IV and oral medicines based on alpha-fetoprotein (AFP) as a tumor targeted carrier for apoptosis inducers.
Small molecule teratogens can damage embryo cells but they are tolerable by adult mothers cells. It is assumed that several teratogens taken with food, medicines or air can bind alpha-fetoprotein (AFP) instead of vital nutrition omega-3 docosahexaenoic acid (DHA). Like AFP-DHA, AFP-teratogen non-covalent complex can cross placenta and be internalized by embryo cells through cell-surface AFP receptor. Majority of cancer cells, unlike normal adult cells re-express AFP receptor and can be damaged by AFP-teratogen complex due to the same delivery mechanism avoiding side effects. AFP-drug non-covalent complexes have shown promising results in cancer patients.